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Structural Insights into the Mode
of Action of a Pure Antiestrogen
Introduction
The estrogen receptor (ER) is a ligand-activated tran-
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Jan-A˚ke Gustafsson,‡ and Mats Carlquist†§ scription factor that mediates the physiological effects
of the female sex steroid hormone 17b estradiol (E2). ER*Structural Biology Laboratory
Chemistry Department is a member of a large group of eukaryotic transcription
factors termed the nuclear receptor (NR) superfamilyUniversity of York
Heslington, York YO10 5DD that share a common structural organization with dis-
tinct domains associated with DNA binding and hor-United Kingdom
†Karo Bio AB mone recognition [1]. Two ER isoforms, ERa [2] and ERb
[3], have been characterized and shown to have distinctNOVUM
S-14157 Huddinge but often overlapping cellular and tissue distribution pat-
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and Biosciences DNA sequences and share significant homology in their
DNA and ligand binding domains. However, ERa andKarolinska Institute
NOVUM ERb have different transcriptional activation properties,
suggesting that they each interact with unique sets ofS-14186 Huddinge
Sweden transcription factors and play different roles in the regu-
lation of gene expression [4–6].
Hormone binding to the ligand binding domain (LBD)
of ER results in a conformation change in the receptor
Summary that allows dimerization, DNA binding, interaction with
coactivators, and, ultimately, the modulation of target
Background: Estrogens exert their effects on target tis- gene transcription [7]. ER exerts its transcriptional effect
sues by binding to a nuclear transcription factor termed through binding to specific estrogen response elements
the estrogen receptor (ER). Previous structural studies (ERE) located in the promoter region of target genes or,
have demonstrated that each class of ER ligand (ago- alternatively, via interacting with other classes of DNA-
nist, partial agonist, and SERM antagonist) induces dis- bound transcription factors such as AP1 [7, 8]. The pre-
tinctive orientations in the receptor’s carboxy-terminal cise mechanism whereby ER affects gene transcription
transactivation helix. The conformation of this portion is poorly understood but appears to be mediated by
of the receptor determines whether ER can recruit and numerous nuclear factors that are recruited by the DNA-
interact with the components of the transcriptional ma- bound receptor [9]. These proteins act as either coacti-
chinery, thereby facilitating target gene expression. vators or corepressors of ER-directed transcription [10].
ER contains two autonomous transcriptional activation
domains [11, 12]. Activation function 1 (AF1), which isResults: We have determined the structure of rat ERb
located in the amino-terminal A/B domain, is regulatedligand binding domain (LBD) in complex with the pure
by growth factors [13], and its activity depends on theantiestrogen ICI 164,384 at 2.3 A˚ resolution. The binding
cellular and promoter environment [14]. In contrast, acti-of this compound to the receptor completely abolishes
vation function 2 (AF2), located in the carboxy-terminalthe association between the transactivation helix (H12)
LBD, is entirely dependent on ligand for activity [14,and the rest of the LBD. The structure reveals that the
15]. However, under most conditions, ligand binding isterminal portion of ICI’s bulky side chain substituent
envisaged to induce functional synergism between AF1protrudes from the hormone binding pocket, binds along
and AF2 [16].the coactivator recruitment site, and physically prevents
A wide repertoire of structurally distinct compoundsH12 from adopting either its characteristic agonist or
bind to ER. Some compounds, such as ER’s endoge-AF2 antagonist orientation.
nous ligand, E2, act as receptor agonists, whereas others
competitively inhibit E2 binding. Such synthetic anties-
Conclusions: The binding mode adopted by the pure trogens (AE) are an important class of clinically relevant
antiestrogen is similar to that seen for other ER antago- compounds [17]. ER antagonists can be divided into
nists. However, the size and resultant positioning of two major classes, depending on their functional effects.
the ligand’s side chain substituent produces a receptor Selective estrogen receptor modulators (SERMs), such
conformation that is distinct from that adopted in the as tamoxifen (OHT) and raloxifene (RAL), have the ability
presence of other classes of ER ligands. The novel ob- to act as both receptor agonists and antagonists, de-
servation that binding of ICI results in the complete pending on the cellular and promoter context as well
destabilization of H12 provides some indications as to as the ER isoform targeted. For example, RAL is an
a possible mechanism for pure receptor antagonism. antagonist in breast and uterine tissue but functions as
Key words: estrogen receptor; ICI 164,384; pure antiestrogen; re-§ To whom correspondence should be addressed (e-mail: rod@
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an agonist in bone and the cardiovascular system [18].
All SERMs appear to act as AF2 antagonists and, at
least for ERa, derive their partial agonist character
through AF1 [6]. A second class, typified by ICI 182,780
and ICI 164,384, are classical “pure” antiestrogens (full
antagonists) capable of completely blocking the activity
of E2 via the inhibition of both AF1 and AF2 action [19,
20]. Such pure antiestrogens are pharmacologically dis-
tinct from RAL and other SERMs. In general, this class
of ER ligand plays an important role as a second-line
therapy against advanced breast cancer in patients who
develop resistance to OHT treatment [21].
Despite a detailed knowledge of the pharmacology of
these different classes of ER antagonists, relatively little
Figure 1. Structure of ERb-LBD in Complex with Pure Antagonistis known about the molecular mechanisms that underlie
ICI 164,384their action. Receptor conformation plays a major role
Ribbon representation of liganded ERb-LBD viewed from the (A)in determining the transcriptional potency and agonist/
side and (B) end on. The two views are related by 908 rotationantagonist character of a given ligand [22]. Different
around the vertical axis. ICI is drawn in space-filling form and colored
pharmacological classes of ER ligand induce distinct according to atom type. Helical elements are numbered (H1–H11),
conformations of the receptor [23, 24]. Both proteolysis and broken lines highlight unmodeled regions of the structure.
and peptide binding studies have indirectly demon-
strated that ICI 164,384 generates a conformational
been solved and fully refined. The conditions understate of the receptor that is unique and different from
which the rERb-ICI complex crystallizes results in a ho-that elicited by agonists and SERMS [22–24]. Further-
modimer arrangement that is somewhat distorted com-more, biochemical studies demonstrate that ICI 164,384
pared to that seen in previous ER ligand complexes.also affects receptor dimerization [25], nucleocytoplas-
PCMBS fosters a network of interactions at the interfacemic shuttling [26], and cellular turnover of ER [27].
between the component monomers of the rERb-LBDStructural studies on the LBD of ER and other NRs
dimer and presumably stabilizes the quaternary struc-have established that NR ligands have a profound effect
ture present in the native crystals.on receptor structure. Hormone binding is accompanied
by a major reorganization in the tertiary structure of the
Monomer StructureLBD [28]. NR agonists elicit a receptor conformation in
The core of the canonical three-layered, antiparallel,which the carboxy-terminal helix (H12), containing the
a-helical sandwich is, as expected, essentially identicalcore region of AF2 [29], is aligned over the hormone
to that observed previously for other ER-LBD ligandbinding cavity and results in the formation of a specific
complexes [32–35]. A central layer of tightly packed,binding site for the consensus LxxLL motif of NR coacti-
antiparallel helices (H5, H6, H9, and H10) is flanked onvators [30, 31]. ER AF2 antagonists, such as RAL and
one side by H7, H8, and H11 and on the other by H2–H4OHT, sterically interfere with this helix positioning and
(Figure 1). The ligand binding cavity, where ICI binds, isprevent the formation of the coactivator recruitment sur-
buried within the hydrophobic core of the LBD immedi-face. Together, these observations have led to the pro-
ately below the central layer of helices. The C-terminalposal of a structural model for AF2 antagonism [32–34].
transactivation helix (H12) is, however, completely invisi-Here, we present a description of the structure of the
ble in the experimental electron density maps. This con-complex between the pure antiestrogen ICI 164,384 and
trasts the situation for all previously determined struc-rat ERb-LBD at 2.3 A˚ resolution. This structure, together
tures for both ER and other NRs, where H12 iswith those already determined for ER, provides a unique
associated with either the same or an adjacent LBDinsight into the relationships between receptor confor-
molecule. Such a destabilization of H12 results directlymation and partial and full antagonism.




ICI is a 7a-alkylamide analog of E2, and its positioningStructure Determination
Crystals of rat ERb-LBD (rERb-LBD) complexed with ICI within the ligand binding cavity is dictated entirely by its
long 7a side chain substituent (Figures 2A–2C). Previous164,384 [ICI; (7a,17b)-N-butyl-3,17-dihydroxy-N-methyl-
estra-1,3,5(10)-triene-7-undecanamide] exhibit a high structural studies on ERa-LBD have identified a narrow
channel (11b channel), which accommodates the analo-degree of internal disorder, which we were unable to
successfully model during refinement (see Experimen- gous bulky side chain groups of SERMs such as RAL
and OHT [32, 33]. This channel is created by the enlarge-tal Procedures). Fortuitously, treatment of the native
crystals with p-chloromercuribenzene sulphonic acid ment of the preformed hydrophobic pocket on the b
face of the cavity on displacement of H12. In order to(PCMBS) results in a disorder-to-order lattice transition
that reduces the contents of the crystallographic asym- accommodate its side chain in a similar manner, ICI
adopts a binding mode whereby its steroidal core ismetric unit from five copies to a single copy of the LBD-
ligand complex. The resultant PCMBS-treated form has flipped 1808 about its longest (hydroxyl-to-hydroxyl)
Structure of an ER-Antagonist Complex
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Figure 2. Binding Mode of Pure Antagonist
(A) Stereoview of ICI (green) bound within rERb-LBD cavity. For clarity, only those residues that line the cavity and/or interact with the bound
ligand are shown. Hydrogen bonds between ICI and protein are represented by dotted lines. Gold mesh represents Fo-Fc omit electron density
map for ICI, calculated using the sigmaa-weighted coefficients output by REFMAC [47] and contoured at 2s.
(B) Schematic representation showing interactions made by ICI. Residues making carbon–carbon van der Waals contacts (d # 3.9 A˚) are
shown in their approximate positions. Interacting atoms/residues are highlighted by green spokes. Ligand atoms are shaded according to
their atomic solvent accessibilities, with completely buried atoms colored orange and exposed atoms in cyan. Accessibilities were calculated
using AREAIMOL [46], and the figure was produced using LIGPLOT [53].
(C) Stereoview of ligand binding modes for ICI (green), E2 (cyan), and RAL (purple). The resultant ligand orientations are shown after superposition
of the LBD atoms alone.
axis, relative to the orientation adopted by the unsubsti- orientation and position of His-430 in the ICI complex
are very similar to the corresponding groups in the rERb-tuted hormone in the hERaE2 complex [32]. This cor-
rectly positions the 7a substituent adjacent to the 11b RAL complex (Figure 2C). This observation not only re-
emphasizes the cavity’s remarkable plasticity but alsochannel so that it can exit the ligand binding cavity
(Figures 2A and 2B). establishes a pattern of preferential binding positions
for the distal hydroxyl of ER ligands.Despite the “flipped” nature of ICI’s steroidal core, the
characteristic hydrogen-bonding interactions between The primary consequence of ICI’s flipped binding
mode, compared to that of E2 (normal mode), is an alter-the protein and ligand are largely unaffected. The A
ring phenolic hydroxyl interacts with the carboxylate of ation in the nonpolar contacts made by the ligand’s
steroidal core. The position adopted by the centralGlu260, a structurally conserved water, and the guani-
dino group of Arg-301, as in the ERa-E2 complex. This framework of ICI readjusts so as to maximally occupy
the cavity and position the ligand’s two hydroxyl groupslatter interaction (3.3 A˚) is presumably weakened some-
what by a shift in the A ring position (see below). Simi- so that they can optimally interact with the protein (Fig-
ure 2B). Consequently, the A ring end of the steroid islarly, the 17b hydroxyl maintains its interaction with His-
430, despite lying on the opposite face of the cavity, shifted laterally away from H3 and toward H6 by about
1 A˚. In contrast, the D ring end of the molecule adoptscompared to the unsubstituted hormone. Interestingly,
both the positioning of the distal 17b hydroxyl and the a very similar spatial position in the flipped and “normal”
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Figure 3. ICI Abolishes Association between
H12 and LBD
(A) Stereoview illustrating how the terminal
portion of the ICI 7a side chain interferes with
H12 positioning. The superposed structures
of the rERb-ICI (green), rERb-RAL (cyan), and
hERa-RAL (magenta) are viewed in the vicin-
ity of the coactivator binding (AF2) groove
between H3 and H5. The respective ligands
and the buried leucine side chains of H12 in
the RAL complexes are drawn in ball-and-
stick form.
(B and C) Close-up view of the AF2 region
in the rERb-ICI complex (B) and rERb-RAL
complex (C). The molecular surface is colored
according to residue type (magenta, hy-
drophobic; blue, all others). Bound ligands
are depicted in space-filling form. Lys-269,
which defines one extremity of the H3/H5
cleft and is critical for ER’s efficient interac-
tion with coactivators and corepressors, is
colored yellow. The positioning of H12 in the
RAL complex is highlighted in red.
orientations (Figure 2C). The ERb cavity accommodates of the LBD formed by residues from helices H3, H4, H5,
and H12 [36, 37]. This region, which is only formed inthese changes with only minimal alterations in the posi-
tioning of the cavity-lining residues. The side chains of the presence of agonist ligands [32, 33], acts as a recruit-
ment surface for nuclear receptor coactivators via spe-Ile-328, His-430, and Leu-431 readjust their positions to
accommodate the repositioned 17b hydroxyl and C18 cific binding of their NR box motifs [30, 31, 33]. The
ligand-dependent nature of AF2 is rooted by the factmethyl groups in a manner reminiscent of that seen in
the ERa and ERb-RAL complexes [34]. that the position of H12 is profoundly influenced by the
nature of the bound receptor ligand. Previous structuralThe N-(n-butyl)-N-methyl-undecanamide side chain
of ICI exits the binding pocket in an identical manner to studies have demonstrated that SERMs such as RAL
and OHT prevent alignment of H12 over the ligand bind-that observed previously for RAL (Figure 2C). However,
once free from the confines of the ligand binding pocket, ing cavity and, instead, redirect it into the NR box binding
cleft between H3 and H5 [32, 33]. In the present struc-the flexible side chain of the ICI antagonist adopts a
conformation that is distinct from that observed with ture, however, the entire polypeptide chain after H11
is invisible in the experimental electron density maps,the corresponding regions of RAL and OHT. The side
chain is bent by z908 at its fifth carbon, so that it closely suggesting that H12 is highly mobile.
The lack of a stable orientation of H12 with respecthugs the contours of the LBD and stacks against the
face of the indole side chain of Trp-290 (Figures 2A and to the LBD can be directly attributed to the binding mode
2B). In addition, the AE’s side chain is considerably of ICI. The protruding 7a substituent of ICI sterically
longer (.6 A˚) than the corresponding region of RAL, prevents alignment of H12 over the cavity, as with other
and this allows it to extend deep into the groove between AF2 antagonists, but, in addition, the positioning of the
H3 and H5. Figure 3B illustrates how the terminal terminal amide portion of the side chain precludes H12
n-butyl group is thrust into a pocket, which is formed by from adopting its alternate orientation along the coacti-
the side chains of Leu-261, Met-264, Ile-265, and Leu- vator binding cleft (Figure 3). As stated previously, the
286, within the shallow H3/H5 hydrophobic groove. end of the ICI side chain nestles in a shallow depression
While the two terminal carbon atoms of the ICI side in the AF2 cleft. This site on the surface of ER-LBD
chain are poorly defined in initial electron density omit serves as a key stabilization point for the binding of H12
maps, the positioning of this portion of the ligand within in either its partial agonist or SERM-induced orientation.
the AF2 cleft is unambiguous. The ICI side chain, unlike Figure 3A illustrates how the positioning of the ICI side
the corresponding regions of RAL and OHT, is not teth- chain sterically prevents H12 from adopting the orienta-
ered to the LBD through an interaction with Asp-258. tion seen in the presence of AF2 antagonists. In the
Consequently, the hydrogen-bonding potential of the ERb-RAL complex [34], this region is occupied by Leu-
amide portion of the side chain is not satisfied by the 446 from the N-terminal end of H12. Similarly, in the
protein, and instead the carbonyl oxygen is directed ERa-RAL complex, where H12 is better defined [32], the
toward the bulk solvent. corresponding site on the LBD surface is occupied by
the side chains of Leu-536 and Leu-540 (Figure 3A).
This region of the AF2 cleft appears to be crucial forConformation of AF2
ER’s ligand-dependent transactivation function (AF2) anchoring the N terminus of H12 in its SERM-induced
orientation. Residues prior to H12, located in the loopcomprises a shallow hydrophobic groove on the surface
Structure of an ER-Antagonist Complex
149
region between H11 and H12, appear to make few, if ture, it is interesting to note that Lys-269, a residue that
is crucial for corepressor binding [39], is not occludedany, contacts with the LBD in the presence of AF2 antag-
onists, and this loop is frequently disordered [32–34]. by H12 and therefore available for interaction (Figures
3B and 3C).Consequently, occlusion of this critical site by ICI ap-
pears to be sufficient to completely prevent H12 associ- A second possible mechanism that may explain the
pure antagonism observed with ICI is that the “liberated”ation with the LBD.
ICI is therefore perfectly tailored to physically block H12 is able to somehow neutralize the function of AF1.
This could be achieved by the displaced H12 directlyboth “docking sites” for H12 on the surface of the LBD.
The significance of ICI’s novel effect on H12 is given interfering with the correct spatial positioning of AF1.
Interestingly, both agonist and OHT-bound ER-LBDs arefurther weight by structure activity studies of the ICI
series of 7a-substituted estradiols, which demonstrate able to promote association between separate N- and
C-terminal domains of ERa [16]. Such ligand-inducedthat the length of the amidoalkyl side chain is crucial for
generating full antagonism [19]. Changes in the length of association is abolished by a single mutation on the
hydrophobic face of H12. This mutation (L540Q), whichthe side chain, which restores some partial agonism,
presumably alter its precise binding mode, thereby is located at a site that is buried when H12 associates
with the LBD, probably has a serious effect on the posi-allowing H12 to associate with the LBD in an orientation
similar to that seen in the RAL and OHT complexes. tioning of the carboxy terminal helix in a manner analo-
gous to ICI. Nevertheless, while H12 is displaced in the
present structure, this does not mean that H12 is neces-
Implications for Pure Antagonism sarily dispensable for pure antagonism. Mutagenesis
Together, these results suggest that the observed posi- studies indicate that an intact AF2 is required for ICI’s
tioning of the ICI side chain and by inference its novel antagonistic effect [44]. While the present structure pro-
effect on H12 are crucial for generating full antagonism. vides some clues as to the mode of action of pure antag-
Most ER antagonists rely on a large side chain substitu- onists, several effects remain unclear. For example, we
ent to confer receptor antagonism [17]. Both RAL and have assumed, for the purposes of the present discus-
ICI’s side chain substituents are too long to be contained sion, that ICI will induce similar conformational perturba-
within the ligand binding cavity, and instead they pro- tions within ERa-LBD. However, ICI appears to have
trude, interfere with H12 alignment, and thereby mani- distinct effects on the conformation of full-length forms
fest AF2 antagonism. However, as mentioned above, of ERa and ERb [45].
ICI is able to inhibit both of ER’s transactivation func- In summary, the molecular mechanisms of AE action
tions (AF1 and AF2). While some residual agonistic activ- are highly complex and known to be dependent on both
ity has been reported for the ICI compounds in vitro [5, receptor conformation and the nature of interacting co-
8], they are able to fully block the partial activity of regulators. While little is known about corepressor re-
SERMs and for all practical purposes can be viewed cruitment to AE-liganded ER, the notion that ICI induces
as full antagonists [17]. Although the present structure a conformation of the receptor that favors corepressor
provides direct evidence for ICI’s effects on AF2, it is binding remains an attractive hypothesis. Undoubtedly,
less clear how abrogation of H12 interaction with the the rapid degradation of ICI-complexed ER [26] plays
LBD influences ER’s N-terminal AF1 functionality. As ICI an important role in determining the pure antagonistic
binding does not result in the blockade of the coactivator character of ICI in vivo. Both the exposure of a large
recruitment site by H12, as occurs with SERMs [32–34], hydrophobic patch on the surface of ER-LBD and the
this region is perhaps able to interact with other nuclear lack of association between H12 and the LBD seen here,
factors. It is conceivable that the displacement of H12 features that are characteristic of either misfolded or
and concomitant exposure of a large hydrophobic patch denatured proteins, probably result in the targeted de-
on the surface of ERb-LBD facilitates corepressor re- struction of the complex by the cellular degradation
cruitment. machinery. The structure of the ERb-ICI complex, and
Recent studies indicate that the corepressor binding those determined for other SERMs [32–34], clearly impli-
site on the surface of NR-LBDs exhibits considerable cate a role for H12 in partial and full ER antagonism.
overlap with the coactivator recruitment site. In fact, Further studies will be required to determine the precise
both NR coactivators and corepressors utilize a similar involvement of the AF2 region in ICI antagonism.
binding motif and seem to share the hydrophobic cleft
between H3 and H5 as part of their binding site [38–40].
There are several similarities between conditions fa- Dimer Organization and Stabilization
As mentioned previously, PCMBS treatment of the na-voring corepressor binding to NRs and those observed
here. Typically, NR corepressors, such as NCoR [41] tive rERb-ICI crystals produces a dramatic lattice disor-
der-to-order transition. Examination of the initial elec-and SMRT [42], have been associated with maintaining
certain NRs in an inactive state in the absence of ligand. tron density maps shows that a single molecule of
PCMBS is covalently attached to Cys-289 located at theIt is noteworthy that, while these corepressors interact
strongly with unliganded receptors, such association is apex of the kinked H5/H6 helix. The PCMBS molecule
is well defined and makes a number of interactions withenhanced by either removal of H12 or addition of recep-
tor antagonists [42]. Furthermore, while unliganded ER the LBD. It binds in a narrow cleft, approximately halfway
up the dyad axis between H5 of one monomer and H11does not interact with classical corepressors [9, 10, 41],
antagonist-bound ER appears to be strongly associated of the crystallographic dimeric partner (Figures 4A and
4B). The benzyl ring of the PCMBS molecule stackswith corepressor, and this association appears to be
indispensable for antagonism [43]. In the present struc- up against Arg-421, and the sulphonate group extends
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Figure 4. PCMBS Binding Site at Dimer Interface
(A) Stereoview of the PCMBS binding site viewed along the dimer interface from the bottom of the LBD. Hydrogen bonds are depicted by
dotted green lines. Helices are shown as coils and colored red and orange (crystallographic dimeric partner; B chain). Interacting residues
are shown in ball-and-stick form and colored according to residue type (carbon, light blue; oxygen, red; sulphur, yellow; nitrogen, dark blue;
mercury, grey).
(B and C) Surface representations of crystallographic dimers for (B) ICI complex and (C) RAL complex (PDB:1QKN). Ligands are represented
in space-filling form and colored according to atom type (carbon, green; oxygen, red; nitrogen, blue). PCMBS, which binds at the dimer interface
in the ICI complex, is shown in stick form. Molecular surfaces were calculated using MOLVIEWER (M. Hartshorn, personal communication) and
are colored according to electrostatic potential (red, negative; blue, positive). Residues Ser-364–Ser-377, which are disordered in the ICI
complex but ordered in the RAL complex, have been omitted from the surface calculation in both cases, so as not to give a false impression
of the differences between the two dimers. Likewise, the side chains of Arg-379 and Lys-380 of the RAL complex, which are disordered in
the ICI complex, are represented by alanines. The position adopted by H12 in the RAL complex is also indicated.
toward and interacts with the LBD’s crystallographic In the rERb-ICI complex, the two component mono-
mers of the crystallographic dimer are splayed out, com-dimer partner. The side chains of Asn-425 (H11) and His-
422 (H11 of the crystallographic dimer partner) sandwich pared to rERb-RAL, resulting in a more open dimer inter-
face (Figures 4B and 4C). One of the componentthe sulphonate moiety and participate in hydrogen
bonds. This network of interactions appears to stabilize monomers rotates away from its partner by about 148
and is shifted upwards by 3–4 A˚ toward the N-terminalthe ER homodimer arrangement present in the native
ICI crystal form and gives rise to the observed lattice end of H11. This monomer repositioning has a minimal
effect on the N-terminal (top) half of interface but a moretransition. A similar heavy metal–induced dimer stabili-
zation has been reported for ERa [35]. pronounced effect on the separation of residues in the
lower half of the interface (Table 1; Figures 4B and 4C).The ERb-LBD monomer within the PCMBS-treated
crystals is oriented so that the LBD dimer axis is coinci- The open nature of the dimer interface in the ICI complex
is also highlighted by the reduction in buried surfacedent with a crystallographic dyad. Comparison of the
resulting crystallographic dimer with similar dimers for area. Whereas a typical ER dimer buries about 15% of
the solvent-accessible surface area of each monomerERb-LBD in the presence of the phytoestrogen genistein
(GEN) and the SERM RAL [34] as well as with noncrys- on formation, the rERb-ICI dimer interface encompasses
only around 10% (1000 A˚2) of each monomer’s surfacetallographic dimers of ERa-LBD in complex with a vari-
ety of agonists and antagonists reveals that the ERb- area.
The origins of the observed dimer distortion in theICI dimer is significantly distorted. Table 1 highlights
the differences in quaternary structure of the ER a/b rERb-ICI complex are not clear. PCMBS treatment of
the native ICI complex crystals does not appear to signif-homodimer in the presence of a variety of ligands.
Structure of an ER-Antagonist Complex
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Table 1. Relative Monomer Orientation between Various ER Homodimers
Monomer Separationa (A˚) Relative Monomer Orientationb
Complexc Dimerd Top Middle Bottom CHI (8)
ERa-E2 N 6.78 4.42 15.55 2
ERa-E2Yale N 6.53 4.42 14.62 2.4
ERa-DES N 6.59 4.30 14.01 1.2
ERa-RAL N 6.33 4.39 13.19 1.6
ERa-OHT C 6.72 4.24 12.68 2.8
rERb-RAL C 7.37 3.95 13.86 3.2
hERb-GEN C 7.47 4.11 11.69 4.9
rERb-ICIe C 5.48 7.17 19.84 13.6
a Intersubunit Ca–Ca separation between each molecule in dimer measured at three positions along H11: Top (His-501 [a], Ser-407 [rERb],
and Ser-452 [hERb]), Middle (Ser-512 [a], Ser-418 [rERb], and Ser-463 [hERb]), and Bottom (Ser-527 [a], Ser-433 [rERb], and Asn-478 [hERb]).
b Difference in orientation of molecule B of each dimer after superposition of molecule A onto corresponding region in ERa-E2 dimer (see
Experimental Procedures). The rotation (CHI) required for optimal superposition is shown.
c PDB accession codes ERa-E2 (1ERE) [32], ERa-E2Yale (1A52) [35], ERa-DES (3ERD) [33], ERa-RAL (1ERR) [32], ERa-OHT (3ERT) [33], rERb-
RAL (1QKN) [34], and hERb-GEN (1QKM) [34].
d Noncrystallographic (N) or crystallographic (C) dimer.
e Values highlighted in bold type relate to structure described here.
icantly affect their physical integrity, suggesting that this receptor activation involves the formation of a specific
coactivator recruitment site on the surface of the LBD.compound only introduces minor structural alterations.
The present structure also clearly demonstrates that The key event in the creation of this site involves the
repositioning of a helical region (H12) located at theICI’s reported effect on receptor dimerization is not a
direct steric one, as previously suggested [25], as the carboxy-terminal end of the LBD. AF2 antagonists pos-
sess a bulky extension that physically prevents H12 fromAE’s long side chain substituent is directed away from
the dimer interface (Figure 4B). Consequently, it is im- adopting the correct position.
In this study, we report the structure of ER-LBD inpossible to say with any certainty whether ICI is respon-
sible for the unusual dimer organization seen here. It is complex with a combined AF1/AF2 (pure) antagonist.
The resultant LBD conformation is fundamentally differ-conceivable that the alteration in quaternary structure
is induced by packing constraints in the crystal rather ent from that observed in the presence of other classes
than by the ligand itself. Examination of the crystal pack-
ing reveals that there is a substantial nondimer interac-
tion between adjacent molecules in the lattice encom- Table 2. Summary of Data Collection, Refinement, and Model
passing z950 A˚2 of each monomer’s surface area. This Validation Statistics for PCMBS-Treated rERb-ICI Complex
packing interaction, which is similar in size to the true
Data Processing
dimer interface, is stabilized by two putative nickel ions
Resolution range (A˚) 20–2.3derived from the crystallization buffer. One of the metals
Observations 185,069lies close to a crystallographic two-fold and interacts
Unique observations 12,201
with His-305 and its symmetry mate. The other ion is Completeness 98.2 (98.6)a
positioned between His-263 and Glu-229 of a symmetry- ,I/s. 14.4 (2)
related molecule. As the presence of nickel is also es- Rmerge (I)b 0.06 (0.326)a
sential for successful crystal growth in this case, it there-
Refinement Statistics
fore seems likely that the observed dimer distortion
Resolution range (A˚) 20–2.3arises as a result of crystal packing forces.
Reflections used (Rfree set) 11,328 (587)
Rcryst (Rfree)c 22.0 (25.1)Biological Implications Protein/ligand atoms 1599/38
Water molecules/other 46/13
The ER is an important drug target for the treatment Rmsd bonds/angles (A˚)d 0.012/0.035
Estimated maximal error (A˚)e 0.221of osteoporosis and breast cancer. A wide variety of
Mean B factorf 53/52/52compounds can bind to and either activate or inhibit ER
% A, B, L (a, b, p, l)g 95.7 (4.3)function, depending on their effects on the receptor’s
a Values in parentheses are for highest resolution shell 2.34–2.3 A˚.two activation functions (AF1 and AF2). The resulting
b Rmerge(I) 5 S|I 2 ,I.|/S,I..balance between receptor agonism and antagonism
c Rcryst 5 S|Fobs 2 Fcalc|/SFobs; Rfree is as Rcryst but calculated over 5%elicited by such ER ligands are central to their therapeu-
of the data that were excluded from the refinement process.
tic effects. A better understanding of the structural d Root-mean-square deviation in bond length and angle distances
events that underlie these processes will facilitate the from Engh and Huber ideal values.
rational design of improved drugs for the targeted treat- e Coordinate error as estimated by SFCHECK [46].
f Mean temperature factor for protein, solvent, and ligand atoms,ment of estrogen-related conditions.
respectively.Crystallographic studies with ER’s LBD have provided
g Percentage of residues located in most favored (additional) regionsa detailed insight into the characteristic structural alter-
of the Ramachandran plot, as determined by PROCHECK [52].
ations that accompany ligand binding. AF2-dependent
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The final model, comprising 1599 protein atoms, 46 water molecules,of ER antagonists. The full antagonist, ICI 164,384 (ICI),
a single PCMBS molecule, and two putative nickel ions, has an Rcrystbinds to ER so as to abrogate completely the interaction
of 0.220 and an Rfree of 0.251. All model building was carried outbetween H12 and the remainder of the LBD. The in-
with the molecular graphics program QUANTA (Molecular Simula-
creased length and resultant positioning of bulky side tions, Inc., San Diego, CA). The final model comprises the entire
chain extension of ICI, compared to AF2 antagonists, is polypeptide chain between Leu-218 and Lys-435, apart from the
flexible loop region between H9 and H10 (residues 364–377). Inprobably responsible for the displacement of H12. The
addition, the LBD’s 21 carboxy-terminal residues, corresponding toobservation that ICI promotes an H12 orientation that
the H11-H12 loop and H12, are also disordered and have not beenis distinct from that seen previously in the presence of
included. Details of the data collection, refinement, and model vali-AF2 antagonists is consistent with these ligands’ con-
dation statistics are given in Table 2.
trasting antagonistic characters and provides some
clues as to the origins of full antagonism. Superpositions
The various structures were superposed using QUANTA. The coordi-
Experimental Procedures nates of the hERa-E2 complex (PDB code:1ERE; molecule A) were
used as the target template for the alignment. After a global align-
Crystallization, Data Collection, and Processing ment based on amino acid sequence identity, superpositions were
Rat ERb-LBD was expressed, purified, and carboxymethylated as fine tuned using the match closest residue option. Differences in
described previously [34]. ICI 164,384 [(7a,17b)-N-butyl-3,17-dihy- the orientation of monomers within the various ERa/b homodimers
droxy-N-methyl-estra-1,3,5(10)-triene-7-undecanamide; CA registry were then determined using LSQKAB [46]. After superposition of
number 98007-99-9] was prepared according to the literature proce- molecule A of the dimer onto 1ERE, the rotation required to overlap
dure of Bowler and coworkers [19]. Crystals were grown using the the second molecule, with respect to the corresponding molecule
hanging-drop vapor diffusion technique at 188C. Drops, comprising in the 1ERE dimer, was calculated by matching equivalent main
equal volumes of protein (10 mg/ml) and reservoir solution (7% chain atoms. Unless stated otherwise, all figures were produced
[w/v] polyethylene glycol 2000 monomethyl ether, 3.5 mM nickel using BOBSCRIPT [50] and RASTER3D [51].
chloride, 10% [v/v] dioxane in 35 mM Tris HCl [pH8.5]), were equili-
brated against the same reservoir solution. The resultant crystals Acknowledgments
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